Neuroscience

Brand Name
Description
Buvidal®
(buprenorphine)
Buvidal® is indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.
Latuda®
(lurasidone hydrochloride)
Latuda® is indicated for the treatment of patients with schizophrenia, for adults aged 18 years and over. Latuda is indicated as monotherapy or as adjunctive therapy with lithium or valproate for acute treatment of depressive episodes associated with bipolar disorder type I in adults. In the treatment of depressive episodes associated with bipolar disorder type I, therapy should be initiated and monitored by a physician with clinical experience in the diagnosis and treatment of affective disorders.
Brand Name
Description
Briviact®
(brivaracetam)
Briviact® is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Neupro®
(rotigotine transdermal patch)
Neupro® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (without levodopa) or in combination with levodopa
Vimpat®
(lacosamide)
Vimpat® is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy and in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
Diseases
Description
Dravet
syndrome
Dravet syndrome is the most severe of a group of conditions known as SCN1A-related seizure disorders. Symptoms include seizures which first occur in infancy that are often triggered by high temperatures known as febrile seizures. In childhood, many types of seizures may occur and they may increase in frequency. Seizures may be difficult to treat. Other symptoms include loss of motor skills, intellectual disability, speech impairment, and difficulty with movement. For more information on available treatment options, please contact us on [email protected]
Lennox-Gastaut
syndrome
Lennox-Gastaut syndrome is a form of severe epilepsy that begins in childhood. It is characterized by multiple types of seizures and intellectual disability. This condition can be caused by brain malformations, perinatal asphyxia (lack of oxygen), severe head injury, central nervous system infection and inherited degenerative or metabolic conditions. In about one-third of cases, no cause can be found. For more information on available treatment options, please contact us on [email protected]
Tuberous sclerosis
complex
Tuberous sclerosis complex (TSC) is characterized by the growth of benign tumors throughout the body, including in the heart, brain, and kidneys. Certain symptoms develop before to birth, such as heart tumors (rhabdomyoma). Other symptoms become more obvious in childhood, such as developmental delay and skin changes. Lung and kidney tumors are more likely to develop in adulthood. For more information on available treatment options, please contact us on [email protected]
  • THE MEDICAL INFORMATION AVAILABLE ON THIS WEBSITE IS FOR GENERAL INFORMATION ONLY AND IS NOT A SUBSTITUTE OR REPLACEMENT FOR A MEDICAL CONSULTATION, NOR DOES IT CONSTITUTE ADVICE, RECOMMENDATION OR SUGGESTION FOR SELF-PRESCRIPTION OR SELF-MEDICATION.
  • USERS SHOULD NOT USE THIS INFORMATION TO ASSESS, DIAGNOSE OR TREAT ANY MEDICAL COMPLAINT AND PATIENTS MUST SEEK PROFESSIONAL ADVICE FROM A QUALIFIED PHYSICIAN BEFORE TAKING ANY ACTION IN RESPECT OF INFORMATION PROVIDED ON THIS WEBSITE.
  • THE AVAILABILITY OF PRODUCTS MARKETED BY NEWBRIDGE MAY VARY BY COUNTRY AND YOU MUST CHECK WITH YOUR LOCAL REGULATORY AUTHORITIES FOR RELEVANT INFORMATION OR VARIATIONS.
  • THIS WEBSITE CONTAINS INFORMATION ABOUT MEDICINAL PRODUCTS REGISTERED REGIONALLY NOT ALL OF THE PRODUCTS AND/OR INDICATIONS THAT ARE MENTIONED ON THE WEBSITE OF NEWBRIDGE ARE AVAILABLE IN ALL THE MARKETS, AS SOME OF THESE PRODUCTS ARE CURRENTLY UNDER REGISTRATION ACROSS THE MENA REGION AND ARE SUBJECT TO APPROVAL ACCORDING TO LOCAL LAWS AND REGULATIONS, AND/OR MAY BE MARKETED BY COMPANIES OTHER THAN NEWBRIDGE PHARMACEUTICALS
  • PLEASE REFER TO YOUR LOCAL NEWBRIDGE PHARMACEUTICAL SATELLITE OFFICE TO ADVISE ON THE AVAILABILITY OF THESE PRODUCTS AND REFER TO COUNTRY SPECIFIC LOCALLY APPROVED PRESCRIBING INFORMATION FOR MORE DETAILS ON THE PRODUCT AND INDICATIONS IN YOUR COUNTRY. THE INFORMATION INCLUDED IN THIS WEBSITE IS NOT INTENDED TO CONSTITUTE PROMOTION IN ANY MANNER OF ANY OF THE DRUGS REFERENCED.
  • THE INFORMATION POSTED ON THIS WEBSITE IS PROVIDED FOR GENERAL INFORMATION PURPOSES ONLY. WHILST NEWBRIDGE PHARMACEUTICALS WILL MAKE EVERY REASONABLE EFFORT TO INCLUDE ACCURATE AND UP-TO-DATE INFORMATION, WE SHALL NOT HOWEVER BE LIABLE IN ANY WAY FOR ERRORS OR OMISSIONS IN THE CONTENTS OF THIS WEBSITE. ALL INFORMATION IS PROVIDED "AS IS". CONSEQUENTLY, THE INFORMATION SHOULD BE CAREFULLY EVALUATED BY SITE VISITORS AND NEWBRIDGE PHARMACEUTICALS DOES NOT PROVIDE ANY WARRANTIES ABOUT COMPLETENESS OR ACCURACY OF THE INFORMATION ON THIS WEBSITE OR ITS POSSIBLE USES.
  • THIS WEBSITE CONTAINS LINKS TO THIRD PARTIES' PAGES OR WEBSITES AND NEWBRIDGE PHARMACEUTICALS MAKES NO REPRESENTATION, NOR DOES IT HAVE ANY RESPONSIBILITY IN RELATION TO ANY MATERIAL OR INFORMATION YOU OBTAIN FROM ANY SUCH PAGES OR WEBSITES.